Home » Topics » BioWorld Science, Infection

BioWorld Science, Infection
RSS

Discovery and preclinical characterization of a novel anti-SARS-CoV-2 MAb, MW-06

Aug. 9, 2021

Dosing begins in phase II portion of phase I/II trial of AKS-452

Aug. 6, 2021

Nullifying necrosis: unfolded protein response inhibitors fight flesh-eating bacteria

Aug. 6, 2021

Enrollment begins in phase II study of Stemedica's itMSCs in patients with COVID-19

Aug. 6, 2021

Aptahem reports positive preliminary results from GLP studies of Apta-1

Aug. 6, 2021

Enanta nominates EDP-235 as clinical candidate for the treatment of COVID-19

Aug. 6, 2021

Qurient initiates phase II study of telacebec in moderate COVID-19

Aug. 5, 2021

New study is both reality check and shot in the arm for SARS-CoV-2 drug repurposing

Aug. 4, 2021

Phase I/II trial cleared to begin in Singapore with ARCT-154 and ARCT-165 for SARS-CoV-2

Aug. 4, 2021

Telmisartan reduces morbidity and mortality in hospitalized patients with COVID-19

Aug. 4, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 30, 2026
CINP 2026: Gut microbiota could predict antidepressant response
BioWorld
The gut microbiota may be altered in people with depression as a result of treatment. These microorganisms reorganize differently in individuals who respond to...
Deep brain stimulation from the shallows: tomorrow’s BCI technology?
BioWorld
Deep brain stimulation (DBS) through implanted electrodes has enabled fundamentally new ways of treating certain disorders. More than 100,000 severely ill...
Ascending BCI systems deepen national security, ethical concerns
BioWorld
Ready or not, the future has arrived. Novel AI and brain-computer interface (BCI) systems are no longer confined to the realm of science fiction. As an...